$6 billion in quarterly sales. $1.1 billion in operating profit. And a CEO who sounds like he’s just warming up.
Q2: Stryker Projects Power, Mako’s Momentum, ASCs
3 min read Premium comments
Stryker CorporationKevin Lobosecond quarter 2025 earnings
Stryker Corporation is in growth mode—again. In its Q2 2025 earnings call, CEO Kevin Lobo and VP of Finance and Investor Relations Jason Beach laid out not just a strong quarter, but a bold full-year outlook that suggests the medtech giant isn’t too worried about tariffs, market jitters, or a few Wall Street raised eyebrows.
| Stryker Corporation 2025 Report ($000s): 3 Months Ended 06/30/25 | ||||||
| 3 Month Sales | 6 Month Sales | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $5,422,000 | $6,020,000 | 11.03% | $10,665,000 | $11,888,000 | 11.47% | |
| Op Profit | Op Profit | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $1,051,000 | $1,113,000 | 5.90% | $2,023,000 | $1,950,000 | -3.61% | |
| 19.38% | 18.49% | 18.97% | 16.40% | |||
| EPS | EPS | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $2.14 | $2.29 | 7.01% | $4.19 | $3.98 | -5.01% | |
| 2025 Sales Estimate | 2026 Sales Estimate | |||||
| Consensus | Change | Consensus | Change | |||
| $22,590,000 | 0.02% | $26,300,000 | 16.40% | |||
Source: RRY Publications LLC
Big Numbers, Bigger Confidence
The headlines:
- $6.02B in revenue—beating the Street
- Organic sales growth of 10.2%
- Adjusted EPS up 11.4%
- Raised full-year guidance
Lobo was blunt: “Strong demand across our product portfolio.” That included double-digit growth in MedSurg and Neurotech, and high single digits in Orthopaedics. U.S. sales growth clocked in at 11.5%, fueled by rising demand in endoscopy, neurocranial, trauma, extremities, and yes—good old hips.
Even with the drag from Inari dilution, spinal implant divestiture, and tariffs, Stryker’s machine kept humming. So much so, they’re targeting another 100 basis points of adjusted operating margin expansion for the year.
Mako Hits 2 Million…and It’s Just Getting Started
The Mako robotic platform continues to be a crown jewel in Stryker’s portfolio. Beach announced a major milestone: two million Mako procedures performed.
And the rollout doesn’t stop there.
“The launches of Mako Spine and Shoulder are going well,” said Beach. “We’re on track for full launches. LifePack 35 and the Pangaea plating system are already making a meaningful impact. Europe just approved LifePack 35, and we’re launching it in Q3.”
Orthopedic execs, take note: Stryker’s not just pushing platforms—they’re building ecosystems.
Analysts: “This Is Bold. Why Now?”
Wall Street had questions. Larry Biegelsen (Wells Fargo) asked what gives Stryker the confidence to raise full-year guidance in a market that’s anything but predictable.
Lobo’s response? “Procedures stayed strong in July. Capital demand is healthy. No slowdown in sight.”
Translation: Hospitals are still buying. ORs are still buzzing. And Stryker’s order book is fat.
ASCs: The Train Has Left the Station
Robbie Marcus (JP Morgan) raised the inevitable ASC question: Are more hospital departments headed outpatient?
Lobo didn’t hesitate. “I don’t think this trend is going to slow down at all,” he said. “It started with sports med and foot and ankle, then hips and knees. Now we’re seeing cardiology and general surgery make the shift.”
And the best part?
“It lowers the cost of healthcare. Surgeons like it. Patients love it. Healthy patients don’t want to be in hospitals. This is the future.”
If you’re not betting on the ASC boom, you’re on the wrong side of the cost curve.
Supply Chain Woes? Still Lingering
Joanne Wuensch (Citibank) asked the tough question: What’s the status of supply chain issues?
Beach acknowledged some “lingering” problems in the Medical division. But he stood firm that double-digit organic sales growth remains on the table. Lobo added that Mako 4 is the next big thing—though not yet a global launch, expect fireworks in 2026.
The Ortho Takeaway
Stryker isn’t just reporting strong numbers—they’re projecting power. While others are cautiously optimistic, they’re confidently aggressive: scaling robotics, investing in ASC infrastructure, and locking in platform wins across Europe and the U.S.
If you’re leading a rival orthopedic enterprise, here’s the message: Stryker’s not waiting for the future of surgery to arrive. They’re shipping it.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.